Loading...

FITC Annexin V

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
AnnexinV_FITC_092908.jpg
Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • AnnexinV_FITC_092908.jpg
    Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • B_AnnexinV_FITC_092908.jpg
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640906 100 tests NOK1601
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640945 300 tests NOK3342
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640905 25 tests NOK685
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (cat. no. 422201) is recommended for use with Annexin V staining.Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat. No. 425305), Helix NP™ Green (Cat.  No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat
Reported Reactivity
Other Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The purified protein was conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Annexin V Staining

  1. Wash cells twice with cold BioLegend Cell Staining Buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x106 cells/mL.
  2. Transfer 100 µL of cell suspension in 5 mL test tube.
  3. Add 5 µL of fluorochrome conjugated Annexin V.
  4. Stain with a viability dye, such as PI (Cat. No. 421301), 7-AAD (Cat. Nos. 420403 & 420404), or Helix NP dyes (Cat. Nos. 425301, 425303, & 425305), if desired.
  5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
  6. Add 400* µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. *For more concentrated samples, add a minimum of 200 µl of Annexin V Binding Buffer in this step.
  7. Analyze by flow cytometry.

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References
  1. Koopman G, et al. 1994. Blood 84:1415.
  2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
  3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
  4. Sekine C, et al. 2009. Int Immunol. PubMed
  5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
  6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
  7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  8. Speth C,et al. 2013. J Infect Dis. 207:823. PubMed
  9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
  11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
  12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed
  13. Sequier S, et al. 2013. PLoS One. 8:70937. PubMed
  14. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  15. Chen YL, et al. 2013. J Exp Med. PubMed
  16. Lin WH, et al. 2014. PLoS One. 9:83160. PubMed
  17. Salge-Bartles U, 2014. Thromb res. 133:244. PubMed
  18. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  19. Intermann J, et al. 2014. Cell Signal. 26:1567. PubMed
  20. de Vires M, 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  21. M Parrula MC, et al. 2014. Virus Res. 189:206. PubMed
  22. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  23. Tsou WI, et al. 2014. J Biol Chem. 289:25750. PubMed
  24. Awojoodu AO, et al. 2014. Blood. 124:1941. PubMed
  25. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  26. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
Product Citations
  1. Derudder E, et al. 2016. Proc Natl Acad Sci U S A. 113: 5065-5070. PubMed
  2. Yao Z, et al. 2018. J Virol. 92:00:00. PubMed
  3. Uriostegui–Arcos M, et al. 2020. Open Biol. 10:200050. PubMed
  4. Zhang T, et al. 2022. EBioMedicine. 77:103872. PubMed
  5. Dhoonmoon A, et al. 2022. Nat Commun. 13:5063. PubMed
  6. Glynn RA, et al. 2022. J Immunol. 208:371. PubMed
  7. Cao H, et al. 2022. Br J Haematol. 198:155. PubMed
  8. Ugamraj HS, et al. 2022. MAbs. 14:2095949. PubMed
  9. Cao L, et al. 2022. Cell Rep. 40:111156. PubMed
  10. Choi UY, et al. 2022. Cell Rep. 40:111234. PubMed
  11. Kimmerling RJ, et al. 2022. Commun Biol. 5:1295. PubMed
  12. Chen X, et al. 2022. Front Pharmacol. 13:1028692. PubMed
  13. Shahid AM, et al. 2022. PLoS One. 17:e0278209. PubMed
  14. Önel T, et al. 2023. Naunyn Schmiedebergs Arch Pharmacol. :. PubMed
  15. Papakonstantinou A, et al. 2022. Int J Mol Sci. 24: . PubMed
  16. Li J, et al. 2023. J Biol Chem. 299:102875. PubMed
  17. Martinelli M, et al. 2023. iScience. 26:105860. PubMed
  18. Tay HG, et al. 2023. Mol Ther. 31:825. PubMed
  19. Dean BD, et al. 2023. J Immunother Cancer. 11: . PubMed
  20. Lieschke E, et al. 2022. Cell Death Differ. 29:1004. PubMed
  21. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  22. Gallego-Murillo JS, et al. 2022. Biotechnol Bioeng. 119:3096. PubMed
  23. Du X, et al. 2023. Nucleic Acids Res. 51:1050. PubMed
  24. Vanoli F, et al. 2023. Oncogenesis. 12:8. PubMed
  25. Lei K, et al. 2023. iScience. 26:106001. PubMed
  26. Ohuchi K, et al. 2023. Biomed Rep. 18:28. PubMed
  27. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  28. Perez GI, et al. 2023. Vaccines (Basel). 11:. PubMed
  29. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  30. Potez M, et al. 2023. Front Oncol. 13:1124272. PubMed
  31. Woodley K, et al. 2023. Nat Commun. 14:2132. PubMed
  32. Quintela M, et al. 2023. Clin Epigenetics. 15:63. PubMed
  33. Quintela M, et al. 2023. Br J Cancer. . PubMed
  34. Lin, R. C., Shao, Z., et al. 2025. Front Immunol. 16(0),1641365. PubMed
  35. Monmai, C., Sabuakham, S., et al. 2025. Biomolecules. 15(10),0. PubMed
  36. Zheng, J., Zhou, J., et al. 2025. Commun Biol. 8(1),1562. PubMed
  37. Skrabanja, T. L. P., Klazen, J. A. Z., et al. 2025. STAR Protoc. 6(4),104204. PubMed
  38. Suwittayarak, R., Nowwarote, N., et al. 2025. Clin Exp Dent Res. 11(6),e70248. PubMed
  39. Xiang, Z., Wu, Y., et al. 2025. Zhejiang Da Xue Xue Bao Yi Xue Ban. 0(0),46031. PubMed
  40. Ortega, M., Agena, E., et al. 2025. Int J Mol Sci. 26(23),0. PubMed
  41. Giustarini, G., Skrabanja, T. L. P., et al. 2025. iScience. 28(12),114076. PubMed
  42. Megawati, E. R., Bangun, H., et al. 2025. Contemp Oncol (Pozn). 29(4),354-359. PubMed
  43. Vesal, M., Moazen Safaei, Y., et al. 2025. Pharmaceutics. 17(12),0. PubMed
  44. Kim EH, et al. 2020. Elife. 9:00. PubMed
  45. Kitayama J, et al. 2016. PLoS One. 11: 0154542. PubMed
  46. Gedye C, et al. 2016. Sci Rep. 6: 25220. PubMed
  47. Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed
  48. Bouhaddou M, et al. 2018. PLoS Comput Biol. 14:e1005985. PubMed
  49. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  50. Dowling CM, et al. 2021. Sci Adv. 7:. PubMed
  51. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  52. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  53. Fujii T, et al. 2015. Proc Natl Acad Sci U S A. 112: 12800 - 12805. PubMed
  54. Cardoso B, et al. 2015. PLoS One. 10: 0143897. PubMed
  55. Alcon C, et al. 2020. Cell Death Dis. 0.898611111. PubMed
  56. Figueiredo T, et al. 2020. Mol Psychiatry. . PubMed
  57. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  58. Feng W, et al. 2017. Nat Commun. 0.697916667. PubMed
  59. Jones PD, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1711. PubMed
  60. Lopes-Coelho F, et al. 2021. Front Oncol. 11:656229. PubMed
  61. Wang Q, et al. 2022. Nat Commun. 13:3022. PubMed
  62. Olelewe C, et al. 2022. iScience. 25:104340. PubMed
  63. Ramalingam P, et al. 2020. J Exp Med. 217:00:00. PubMed
  64. Bowen ME, et al. 2019. Dev Cell. 50:212. PubMed
  65. Sales–Dias J, et al. 2019. PLoS One. 14:e0217002. PubMed
  66. Santos LC, et al. 2019. Nat Commun. 1.328472222. PubMed
  67. Lim JA, et al. 2018. BMC Cancer. 0.860416667. PubMed
  68. Venter C, et al. 2017. Cell Physiol Biochem. 43:1288. PubMed
  69. Kim Y, et al. 2020. J Neurochem. 155:177. PubMed
  70. Hassan MIA, et al. 2021. Comput Struct Biotechnol J. 19:880. PubMed
  71. Soprano M, et al. 2016. PLoS One. 11: 0155970. PubMed
  72. Macpherson L, et al. 2020. Nature. 577:266. PubMed
  73. Karavasili C, et al. 2017. International Journal of Pharmaceutics. 10.1016/j.ijpharm.2017.05.061. PubMed
  74. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  75. Noguchi F, et al. 2017. Mol Cancer Ther. 1.316666667. PubMed
  76. Kumar S, et al. 2018. Cancers (Basel). 0.724305556. PubMed
  77. Fortin J, et al. 2020. Cancer Cell. 37:308. PubMed
  78. Vereertbrugghen A, et al. 2021. Front Oncol. 11:598319. PubMed
  79. Sun V, et al. 2021. Front Immunol. 12:716661. PubMed
  80. Coray M, et al. 2022. Int J Mol Sci. 23:. PubMed
  81. He C, et al. 2021. Oncoimmunology. 1897295:10. PubMed
  82. Pfalzgraff A, et al. 2016. Sci Rep. 6:31577. PubMed
  83. O'Neill K, et al. 2016. Genes Dev. 30: 973-988. PubMed
  84. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
  85. Vries M, et al. 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  86. Chen MS, et al. 2019. Mol Cancer Res. 17:697. PubMed
  87. Ni F, et al. 2019. Cell Stem Cell. 24:608. PubMed
  88. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  89. Greenblatt SM, et al. 2018. Cancer Cell. 33:1111. PubMed
  90. Naqvi N,et al. 2017. Sci Rep.. 10.1038/s41598-017-12753-1. PubMed
  91. Wang M, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.097. PubMed
  92. Beeravolu N, McKee C, Chaudhry G 2017. J App Toxicol. 10.1002/jat.3469. PubMed
  93. Kim OV, et al. 2022. iScience. 25:104654. PubMed
  94. Shahzadi SK, et al. 2022. Clin Sci (Lond). 136:181. PubMed
  95. Kolbrink B, et al. 2022. Biochem J. 479:259. PubMed
  96. Parrula M, et al. 2014. Virus Res. 189:206. PubMed
  97. Brigger D, et al. 2015. Cell Death Dis. 6: e1861. PubMed
  98. Zhang J, et al. 2016. Cell Death Dis. 7:e2266. PubMed
  99. Wang D, et al. 2016. J Cell Sci. 129: 2261 - 2272. PubMed
  100. Uchtenhagen H, et al. 2016. Nat Commun. 7:12614. PubMed
  101. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  102. Esteghamat F, et al. 2019. Nat Genet. 51:1233. PubMed
  103. Blümel E, et al. 2020. Oncoimmunology. 9:1751561. PubMed
  104. Sekine C, et al. 2009. Int Immunol. 1.079861111. PubMed
  105. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  106. O'Connor MJ, et al. 2021. Oncogene. 40:4872. PubMed
  107. Madala HR, et al. 2020. Cancer Res. 3492:80. PubMed
  108. Clements KE, et al. 2020. Nat Commun. 4.706944444. PubMed
  109. Rauzan M, et al. 2017. PLoS One. 12:e0174107. PubMed
  110. Liu Y, et al. 2017. Acta Biomater. 10.1016/j.actbio.2017.08.021. PubMed
  111. Chiani M, et al. 2017. Artif Cells Nanomed Biotechnol. 10.1080/21691401.2017.1337029. PubMed
  112. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  113. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  114. Schmitz RL, et al. 2021. Cells. 10:. PubMed
  115. Babaei A, et al. 2021. Adv Pharm Bull. 11:361. PubMed
  116. Salge-Bartels U, et al. 2014. Thromb Res. 133:244. PubMed
  117. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  118. Ligtenberg M, et al. 2016. J Immunol. 196: 759 - 766. PubMed
  119. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  120. Herold N, et al. 2017. Nat Med. 23:256-263. PubMed
  121. Xie S, et al. 2021. Sci Rep. 0.660416667. PubMed
  122. Müller I, et al. 2020. Mol Cell. 970:77. PubMed
  123. Kamiyama N, et al. 2017. Antiviral Res. 10.1016/j.antiviral.2017.08.007. PubMed
  124. Montero–Herradón S, et al. 2017. Organogenesis. 0.675. PubMed
  125. Nunes SC, et al. 2018. Sci Rep. 6.939583333. PubMed
  126. Sharif T, et al. 2018. Autophagy. 1.101388889. PubMed
  127. Eichelmann AK, et al. 2018. Sci Rep. 8:17553. PubMed
  128. Blümel E, et al. 2019. Oncoimmunology. 8:e1641387. PubMed
  129. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  130. Norkin M, et al. 2021. Cell Rep. 35:109026. PubMed
  131. Krauss PL, et al. 2021. Front Immunol. 12:730672. PubMed
  132. Zhu Y, et al. 2022. Clin Transl Med. 12:e887. PubMed
  133. Khatib JB, et al. 2022. Oncotarget. 13:1078. PubMed
  134. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  135. Chheda Z, et al. 2016. J Immunol. 197: 2016 - 2026. PubMed
  136. Slone E, et al. 2015. J Leukoc Biol. 98: 791 - 804. PubMed
  137. Séguier S, et al. 2013. PLoS One. 8:70937. PubMed
  138. Liu H, et al. 2020. Cell Death Dis. 0.767361111. PubMed
  139. Zervou S, et al. 2017. PLoS One.. 10.1371/journal.pone.0182994. PubMed
  140. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  141. Matsuda K, et al. 2021. Cell Rep Methods. 1:100122. PubMed
  142. Vanoli F, et al. 2021. Oncogene. 40:5095. PubMed
  143. Liu H, et al. 2021. J Immunother Cancer. 9:. PubMed
  144. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  145. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  146. Meyer N, et al. 2021. J Clin Med. 10:. PubMed
  147. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  148. Douguet L, et al. 2016. PLoS One. 11:e0166164. PubMed
  149. Toutounchian J, et al. 2016. Mol Pharmacol. 91(1):1-13. PubMed
  150. Pajarillo E, et al. 2020. J Biol Chem. 295:3040. PubMed
  151. Litzenburger UM, et al. 2017. Genome Biol. 18:15. PubMed
  152. Rajavel T, et al. 2017. Sci Rep. 2.665277778. PubMed
  153. Grujic M, et al. 2010. J Immunol. 185:1730. PubMed
  154. Gholamrezaei M, et al. 2021. Iran J Parasitol. 15:475. PubMed
  155. Meyer N, et al. 2021. Int J Mol Sci. 22:. PubMed
  156. Kolbrink B, et al. 2022. Cell Mol Life Sci. 79:387. PubMed
  157. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  158. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. PubMed
  159. Becker A, et al. 2016. Sci Rep. 6: 33847. PubMed
  160. Kumai T, et al. 2015. Sci Rep. 5:16280. PubMed
  161. Polak R, et al. 2015. Blood. 126: 2404 - 2414. PubMed
  162. Matsumoto A, et al. 2019. J Extracell Vesicles. 9:1696517. PubMed
  163. Pirali T, et al. 2017. ChemMedChem. 1.570833333. PubMed
  164. Ishida M, et al. 2021. Int J Mol Sci. 22:. PubMed
  165. Lee DH, et al. 2020. Circ Res. 127:1182. PubMed
  166. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  167. Tsou W, et al. 2014. J Biol Chem. 289:25750. PubMed
  168. Dhoonmoon A, et al. 2020. Nucleic Acids Res. 48:7252. PubMed
  169. Hafez A, et al. 2017. Oncogenesis. 10.1038/oncsis.2017.46. PubMed
  170. Putheti P, et al. 2010. PLoS One. 5:e8706. PubMed
  171. Nastasi C, et al. 2021. Sci Rep. 11:1458. PubMed
  172. Molinar-Inglis O, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  173. Erdogan M, et al. 2022. Chem Biodivers. 19:e202200659. PubMed
  174. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  175. Liu B, et al. 2016. J Biol Chem. 291: 23869 - 23881. PubMed
  176. Lhuillier C, et al. 2015. J Biol Chem. 290: 16797 - 16811. PubMed
  177. Passaro C, et al. 2013. Endocr Relat Cancer. 20:633. PubMed
  178. Mulik R, et al. 2010. Int J Pharm. 398:190. PubMed
  179. Speth C, et al. 2013. J Infect Dis. 207:823. PubMed
  180. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  181. Lee HW, et al. 2018. Am J Physiol Renal Physiol. 314:F280. PubMed
  182. Ki H, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.09.118. PubMed
  183. Shadboorestan A, et al. 2022. Iran J Basic Med Sci. 25:506. PubMed
  184. Huang Y, et al. 2022. Front Cell Dev Biol. 9:837777. PubMed
  185. Babaei A, et al. 2020. Daru. 28:555. PubMed
  186. King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed
  187. Lin W, et al. 2014. PLoS One. 9:83160. PubMed
  188. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  189. CO L, et al. 2015. Nat Commun. 6: 7739. PubMed
  190. Huang YL, et al. 2020. Elife. 9:00. PubMed
  191. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  192. Di Somma S, et al. 2019. Cancers (Basel). 1.70625. PubMed
  193. Abu El Maaty MA, et al. 2021. Sci Adv. 7: . PubMed
  194. Bahl S, et al. 2021. Cell Death Dis. 12:469. PubMed
  195. Jackson LM, et al. 2021. Nucleic Acids Res. 49:12855. PubMed
  196. Faria M, et al. 2017. PLoS One. 12(2):e0172689. PubMed
  197. Jones P, et al. 2016. J Biol Chem. 291: 16318 - 16327. PubMed
  198. Awojoodu A, et al. 2014. Blood. 124:1941. PubMed
  199. Intemann J, et al. 2014. Cell Signal. 26:1567. PubMed
  200. Labi V, et al. 2019. Genes Dev. 33:1673. PubMed
  201. Fang P, et al. 2019. Commun Biol. 0.315972222. PubMed
  202. Kumar S, et al. 2019. Int J Cancer. 146:1652. PubMed
  203. Zhao CC, et al. 2018. Oncol Rep. 40:3392. PubMed
  204. Schleicher EM, et al. 2018. Nucleic Acids Res. 46:8908. PubMed
  205. Thomas A, et al. 2017. PLoS One.. 10.1371/journal.pone.0183542. PubMed
  206. Tatangelo V, et al. 2022. Front Oncol. 12:877495. PubMed
  207. Alcon C, et al. 2021. Cells. 10:. PubMed
  208. Cao H, et al. 2021. Nat Commun. 12:1792. PubMed
  209. Clements KE, et al. 2018. Nucleic Acids Res. 46:8898. PubMed
  210. Bostanabad SY, et al. 2021. Sci Rep. 11:1539. PubMed
  211. Monzen S, et al. 2022. Mol Clin Oncol. 16:19. PubMed
  212. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
  213. Wu J, et al. 2021. Adv Sci (Weinh). 8:e2101029. PubMed
  214. Zhang Y, et al. 2021. Cell Death Dis. 0.563194444. PubMed
  215. Kang JH, et al. 2020. Cell Death Dis. 0.803472222. PubMed
  216. Dewdney B, et al. 2020. Sci Rep. 10:16769. PubMed
  217. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  218. Coutaz M, et al. 2016. Sci Rep. 6:39117. PubMed
  219. Akane K, et al. 2016. Proc Natl Acad Sci U S A. 113: 2460 - 2465. PubMed
  220. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  221. Chen Y, et al. 2013. J Exp Med. 210:2515. PubMed
  222. Mendès C, et al. 2019. Sci Rep. 9:14107. PubMed
  223. Lopes–Coelho F, et al. 2017. Oncotarget. 8:82803. PubMed
  224. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  225. Thanuthanakhun N, et al. 2017. PLoS One. . 10.1371/journal.pone.0187610. PubMed
  226. Kuntz E, et al. 2017. Nat Med. 10.1038/nm.4399. PubMed
  227. Tu Z, et al. 2022. Cell Rep. 40:111072. PubMed
  228. Bensberg M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  229. Paparella AS, et al. 2021. Nat Commun. 12:6285. PubMed
  230. Huang YL, et al. 2021. iScience. 24:103168. PubMed
  231. Bottardi S, et al. 2020. Exp Hematol. 68:88. PubMed
  232. Siddhartha V, et al. 2017. Artif Cells Nanomed Biotechnol . 10.1080/21691401.2017.1313267. PubMed
  233. He J, et al. 2017. FASEB J. 31:2893. PubMed
  234. Lyu X, et al. 2019. BMC Genomics. 1.235416667. PubMed
  235. Jing Y, et al. 2019. J Allergy Clin Immunol. 144:1377. PubMed
  236. Quan M, et al. 2019. Oncol Rep. 41:3051. PubMed
  237. Kasikara C, et al. 2021. J Clin Invest. 131:. PubMed
  238. Ning N, et al. 2022. Theranostics. 12:5537. PubMed
  239. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  240. Pahari S, et al. 2020. Autophagy. 1.375694444. PubMed
  241. Schleicher EM, et al. 2020. PLoS Genet. 16:e1009176. PubMed
  242. Langsch S, et al. 2016. Cancer Res . 76: 4160 - 4169. PubMed
  243. Xiong R, et al. 2015. Mol Pharmacol. 88: 1045 - 1054. PubMed
  244. Hellmann J, et al. 2013. J Immunol. 191:1383. PubMed
  245. Juel H, et al. 2013. PLoS One. 8:64619. PubMed
  246. Gill K, et al. 2013. Biochim Biophys Acta. 1830:2763. PubMed
  247. Young MM, et al. 2019. Cell Death Dis. 1.004861111. PubMed
  248. Santos I, et al. 2019. Nutrients. 2.210416667. PubMed
  249. Vancsik T, et al. 2019. Cancer Med. 3.313888889. PubMed
  250. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  251. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  252. Wang Y, et al. 2022. Front Cardiovasc Med. 9:876087. PubMed
  253. Shankman LS, et al. 2021. Curr Biol. 31:2469. PubMed
RRID
AB_2561292 (BioLegend Cat. No. 640906)
AB_2629519 (BioLegend Cat. No. 640945)
AB_2561291 (BioLegend Cat. No. 640905)

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID
UniProt
View information about Annexin V on UniProt.org

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 7    Revision Date: 10.22.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account